Genfit and Ipsen announce elafibranor results
ELATIVE, a randomised PBC trial involving 161 patients, has successfully met its primary endpoint
Read Moreby John Pinching | Jun 30, 2023 | News | 0
ELATIVE, a randomised PBC trial involving 161 patients, has successfully met its primary endpoint
Read Moreby John Pinching | Apr 5, 2023 | News | 0
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Read Moreby John Pinching | Feb 14, 2023 | News | 0
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
Read Moreby John Pinching | Nov 9, 2022 | News | 0
Onivyde regimen demonstrated statistically significant improvement in overall survival
Read Moreby John Pinching | Aug 1, 2022 | News | 0
Deal will advance precision immuno-oncology candidates from Marengo’s STAR platform
Read Moreby Anna Smith | Aug 9, 2019 | News | 0
Good news for adult patients with gastroenteropancreatic neuroendocrine tumours.
Read Moreby Anna Smith | Feb 25, 2019 | News | 0
Ipsen has announced plans to acquire Clementia Pharmaceuticals.
Read Moreby Selina McKee | Nov 15, 2018 | News | 0
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read Moreby Selina McKee | Aug 29, 2018 | News | 0
NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.
Read Moreby Selina McKee | Jun 5, 2018 | News | 0
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read Moreby Selina McKee | May 17, 2018 | News | 0
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read Moreby Selina McKee | Mar 28, 2018 | News | 0
Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479